Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009)

NCT00704405 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

285

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

DRUG: Vaniprevir
DRUG: Pegylated Interferon (Peg-IFN)
DRUG: Ribavirin (RBV)
DRUG: Placebo (PBO)

Sponsor

Merck Sharp & Dohme LLC